Catalog No.S7655

CB-839 Chemical Structure

Molecular Weight(MW): 571.57

CB-839 is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. Phase 1.

Size Price Stock Quantity  
USD 147 In stock
USD 477 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

4 Customer Reviews

  • Apoptotic sensitivity of K562 resistant (E) cells exposed to A1331852 (10 nM) for 4 h was restored following pharmacological inhibition of glutamine uptake or metabolism with GPNA (5 mM) for 48 h, CB-839 (10 μM) for 72 h, azaserine (25 μM) for 16 h and AOA (500 μM) for 24 h but not with EGCG (50 μM) for 24 h. Western blots confirmed the knockdown efficiency of the different siRNAs. ***P<0.001, **P<0.01; Error bars = Mean ± SEM (n=3).

    Haematologica, 2018, doi:10.3324/haematol.2018.204701. CB-839 purchased from Selleck.

    c. Indicated cell lines were treated with 0, 20 or 200 nM CB-839 in the presence or absence of FBS. In the absence of FBS, all cell lines are more sensitive for inhibition with CB-839, especially the IDH1/2 mutant cell lines.

    Br J Cancer, 2018, 118(8):1074-1083. CB-839 purchased from Selleck.

  • GLS1 inhibition blocked glutamine (Gln)-mediated increases in intracellular glutamate and proliferation of HUVECs. (A) Gln-mediated increases in intracellular glutamate were inhibited by GLS1 inhibitors. HUVECs were incubated with Gln in the presence or absence of DON (20 µM), BPTES (20 µM), or CB-839 (20 µM) for 24 h. (B) DON inhibited the proliferation of HUVECs in a concentration-dependent manner. (C) BPTES inhibited the proliferation of HUVECs in a concentration-dependent manner. (D) CB-839 inhibited the proliferation of HUVECs in a concentration-dependent manner. For the proliferation experiments, HUVECs were incubated in the presence or absence of GLS1 inhibitors for three days. Results are means ± SD (n = 6). *Statistically significant effect of GLS1 inhibitors. +Statistically significant effect of Gln.

    Biochem Pharmacol, 2018, 156:204-214. CB-839 purchased from Selleck.

    Combination treatment with a GLS1 inhibitor and PP242 induces cell death. a The SKOV3 and A2780 cells were incubated with DMSO (control), PP242 (1 μM), CB839 (1 μM), or their combination for 48 h. Cell morphology images were obtained under a microscope. b. Expression of the activated cleaved PARP content to GAPDH was observed using Western blot. c. Cell death was evaluated by flow cytometry after Annexin V and PI staining. Data are presented as means of triplicate samples, and error bars reflect SD.

    Tumor Biol, 2016, 37:11007-11015.. CB-839 purchased from Selleck.

Purity & Quality Control

Choose Selective Glutaminase Inhibitors

Biological Activity

Description CB-839 is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. Phase 1.
Glutaminase [1]
(Cell-free assay)
24 nM
In vitro

CB-839 exhibits time-dependent and slowly reversible kinetics. IC50 values for glutaminase inhibition by CB-839 following preincubation with rHu-GAC for-1 hour are < 50 nmol/L, at least 13-fold lower than with BPTES. CB-839 has antiproliferative activity in a triple-negative breast cancer (TNBC) cell line, HCC-1806, while no antiproliferative activity is observed in an estrogen receptor–positive cell line, T47D.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 cells MmGzR5l1d3SxeHnjbZR6KGG|c3H5 MnrROkBl[Xm| MlHoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDt[YF{fXKnZDDvckA3fGhiZHH5JIJ6KGinbX;jfZRwdWW2comsJGlEPTB;MD6wN|Mh|ryP MV6yOlk5QDhyMx?=
MM.1S BzR cells MXnGeY5kfGmxbjDhd5NigQ>? M2nMNVUh|ryP MkTlNVYhcG:3coO= Mm\EeJJm[XSvZX70JJdqfGhiQ1KtPFM6KHOrZ37p[olk[W62bImgdoVxemW|c3XkJI95gWenbjDjc45{fW2ydHnvckBz[XSnIHnuJJBzd3SnYYPvcYUucW6qaXLpeI9zKHKnc3nzeIFvfCClZXzsd{4> NGX3V3YzQDRzNUe4Ni=>
MM.1S cells NHvvfY9E\WyuII\pZYJqdGm2eTDhd5NigQ>? MYO3NkBpd3W{cx?= NELXWVYzQDRzNUe4Ni=>
U266 cell lines M4DQb2NmdGxidnnhZoltcXS7IHHzd4F6 MW[3NkBpd3W{cx?= NVPWOW4zOjh2MUW3PFI>

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
collagen I/collagen III; 

PubMed: 29019707     

Idiopathic pulmonary fibrosis lung fibroblasts were treated with or without 1 μM CB-839 for 48 hours. The amounts of indicated proteins were determined by Western blotting. 

Growth inhibition assay
Cell growth; 

PubMed: 28967864     

Proliferation of various KEAP1 wild type human cancer cell lines. Cells were pretreated with 1 μM KI696 where indicated followed by 250 nM CB-839 treatment for 5 days. All data is presented as relative to the untreated condition for each cell line (n = 3, triplicate wells). All error bars depict s.e.m. ****p<0.0001.

In vivo In the mouse TNBC model, single agent CB-839 (200 mg/kg, p.o.) suppresses tumor growth by 61% relative to vehicle control. In the mouse JIMT-1 xenograft model, CB-839 alone (200 mg/kg, p.o.) results in 54% tumor growth inhibition (TGI) relative to vehicle control, combination of CB-839 (200 mg/kg, p.o.) with paclitaxel (10 mg/kg, p.o.) largely suppresses the regrowth of the tumors resulting in a TGI relative to vehicle control of 100%.[1]


Kinase Assay:


+ Expand

Inhibition of CB-839 on rHu-GAC:

The enzymatic activity is measured in assay buffer containing 50 mM Tris-Acetate pH 8.6, 150 mM K2HPO4 , 0.25 mM EDTA, 0.1 mg/mL bovine serum albumin, 1 mM DTT, 2 mM NADP+ and 0.01% Triton X-100. To measure inhibition, the inhibitor (prepared in DMSO) is first pre-mixed with glutamine and glutamate dehydrogenase (GDH) and reactions are initiated by the addition of rHu-GAC. Final reactions contains 2 nM rHu-GAC, 10 mM glutamine, 6 units/mL GDH and 2% DMSO. Generation of NADPH is monitored by fluorescence (Ex340/Em460 nm) every minute for 15 minutes on a SpectraMax M5e plate reader. Relative fluorescence units (RFU) are converted to units of NADPH concentration (µM) using a standard curve of NADPH. Each assay plate incorporates control reactions that monitores the conversion of glutamate (1 to 75 µM) plus NADP+ to α-ketoglutarate plus NADPH by GDH. Under these assay conditions, up to 75 µM glutamate is stoichiometrically converts to α-ketoglutarate/NADPH by GDH. Initial reaction velocities are calculated by fitting the first 5 minutes of each progress curve to a straight line. Inhibition curves are fitted to a four-parameter dose response equation of the form: % activity = Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)).
Cell Research:


+ Expand
  • Cell lines: HCC1806, MDA-MB-231, and T47D cells
  • Concentrations: 0.1-1000 nM
  • Incubation Time: 72 h
  • Method:

    For viability assays, all cell lines are treated with CB-839 at the indicated concentrations for 72 hours and analyzed for antiproliferative effects using Cell Titer Glo.

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: Female Scid/Bg mice bearing TNBC or JIMT-1 xenograft
  • Formulation: 25% (w/v) hydroxypropyl-b-cyclodextrin (HPBCD) in 10 mmol/L citrate, pH 2
  • Dosages: 200 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (174.95 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 571.57


CAS No. 1439399-58-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03875313 Recruiting Drug: CB-839|Drug: Talazoparib Solid Tumor|Clear Cell Renal Cell Carcinoma|TNBC - Triple-Negative Breast Cancer|Colorectal Cancer|CRC|RCC|ccRCC Calithera Biosciences Inc March 22 2019 Phase 1|Phase 2
NCT02944435 Completed Drug: CB-839 Capsules|Drug: CB-839 Tablets Healthy Volunteers Calithera Biosciences Inc October 2016 Phase 1
NCT02771626 Recruiting Drug: CB-839|Drug: Nivolumab Clear Cell Renal Cell Carcinoma|Melanoma|Non-small Cell Lung Cancer Calithera Biosciences Inc August 2016 Phase 1|Phase 2
NCT02071927 Completed Drug: CB-839|Drug: CB-Aza Acute Myeloid Leukemia (AML)|Acute Lymphocytic Leukemia (ALL) Calithera Biosciences Inc March 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy CB-839 | CB-839 supplier | purchase CB-839 | CB-839 cost | CB-839 manufacturer | order CB-839 | CB-839 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID